Elemento Lab

Author Correction: Neoadjuvant durvalumab plus radiation versus durvalumab alone in stages I-III non-small cell lung cancer: survival outcomes and molecular correlates of a randomized phase II trial.

Submitted by ole2001 on February 6, 2026 - 12:43am
TitleAuthor Correction: Neoadjuvant durvalumab plus radiation versus durvalumab alone in stages I-III non-small cell lung cancer: survival outcomes and molecular correlates of a randomized phase II trial.
Publication TypeJournal Article
Year of Publication2024
AuthorsAltorki NK, Walsh ZH, Melms JC, Port JL, Lee BE, Nasar A, Spinelli C, Caprio L, Rogava M, Ho P, Christos PJ, Saxena A, Elemento O, Bhinder B, Ager C, Amin ADipak, Sanfilippo NJ, Mittal V, Borczuk AC, Formenti SC, Izar B, McGraw TE
JournalNat Commun
Volume15
Issue1
Pagination225
Date Published2024 Jan 03
ISSN2041-1723
DOI10.1038/s41467-023-44575-3
Alternate JournalNat Commun
PubMed ID38172131
PubMed Central IDPMC10764801
Grant ListS10 OD032433 / OD / NIH HHS / United States
U54 CA274506 / CA / NCI NIH HHS / United States